(Total Views: 537)
Posted On: 10/30/2021 5:46:37 PM
Post# of 155735
Re: craigakess #109236
Craig,
You are the attorney, not I. However, to review, my understanding is that suit by Cytodyn against Amarex seeks an injunction compelling release of data without which current trials will halt and patients receiving Leronlimab will be injured by cessation of treatment.
The release of these likely incomplete collection of emails by Amarex seems intended to inflict injury on Dr Pourhassan. Even if these emails reflect an accurate portrayal of the communications between Amarex amd Dr Pourhassan, I would be surprised if these are sufficient to prevent the court from compelling the release of data by Amarex to Cytodyn.
There remains plenty of opportunity for Amarex to force payment for services they believed they have performed appropriately for Cytodyn.
That is my assessment.
Is it your belief that the court would permit Amarex to withhold data, injure patients and upend clinical trials if Dr Pourhassan was demonstrated to have inappropriately cajoled Amarex into a premature BLA filing?
Would his alleged bad behavior be sufficient to overturn the responsibility of Amarex to maintain and share the data collected on behalf of Cytodyn?
You are the attorney, not I. However, to review, my understanding is that suit by Cytodyn against Amarex seeks an injunction compelling release of data without which current trials will halt and patients receiving Leronlimab will be injured by cessation of treatment.
The release of these likely incomplete collection of emails by Amarex seems intended to inflict injury on Dr Pourhassan. Even if these emails reflect an accurate portrayal of the communications between Amarex amd Dr Pourhassan, I would be surprised if these are sufficient to prevent the court from compelling the release of data by Amarex to Cytodyn.
There remains plenty of opportunity for Amarex to force payment for services they believed they have performed appropriately for Cytodyn.
That is my assessment.
Is it your belief that the court would permit Amarex to withhold data, injure patients and upend clinical trials if Dr Pourhassan was demonstrated to have inappropriately cajoled Amarex into a premature BLA filing?
Would his alleged bad behavior be sufficient to overturn the responsibility of Amarex to maintain and share the data collected on behalf of Cytodyn?
(11)
(0)
